ECM
ABBV icon

ExodusPoint Capital Management’s AbbVie ABBV Stock Holding History

ExodusPoint Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,100
Closed -$3.57M – 1394
2024
Q4 		$3.57M Buy
20,100
+18,500
+1,156% +$3.4M 0.02% 542
2024
Q3 		$316K Sell
1,600
-19,100
-92% -$3.56M ﹤0.01% 1345
2024
Q2 		$3.55M Buy
20,700
+4,500
+28% +$745K 0.02% 559
2024
Q1 		$2.94M Buy
+16,200
New +$2.79M 0.02% 563

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

ExodusPoint Capital Management's ABBV Position: Q2 2025 in Review

ExodusPoint Capital Management sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 51,628 shares — an estimated $10.8M sold.

ExodusPoint Capital Management first reported a position in ABBV in Q2 2019 and held it in 19 quarters. The position peaked at $43.5M in Q2 2023. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • ExodusPoint Capital Management reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 51,628 AbbVie shares in Q2 2025, an estimated $10.8M.
  • ExodusPoint Capital Management first reported a position in AbbVie in Q2 2019 and held it in 19 quarters.
  • ExodusPoint Capital Management's AbbVie position peaked at $43.5M in Q2 2023.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.